Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid

Detalles Bibliográficos
Autores principales: Ferrari, Michel D., Zuurbier, Karin W. M., Barash, Steve, Ning, Xiaoping, Cohen, Joshua M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322527/
https://www.ncbi.nlm.nih.gov/pubmed/35383922
http://dx.doi.org/10.1111/head.14294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322527/
https://www.ncbi.nlm.nih.gov/pubmed/35383922
http://dx.doi.org/10.1111/head.14294

Ejemplares similares